Unknown Analyst
Good morning, all, and welcome. My name is [ Fazi Kash], and I’ll be moderating today’s session. It is my pleasure to introduce Eric Green, President, CEO and Board Chair; Bob McMahon, CFO; and John Sweeney, VP of IR of West to the JPMorgan conference. And without further ado, I’ll hand it over to Eric.
Eric Green
Non-Independent Chair of the Board, President & CEO
All right. [ Fazi], thank you so much for the introduction, and thank you for the invitation for the JPMorgan Conference. Happy New Year to everybody, and it’s a great start to 2026.
Before I get started into the West discussion, I want to just reference the safe harbor statement that’s found on this presentation, also found at our website at westpharma.com.
I’m going to talk a little bit about West. It’s a phenomenal story over several decades of where we are today, but more importantly, where we’re going. If you think of from an investment portfolio perspective, we are the global leader in the injectable medicine space with what we provide each and every day. We have developed a significant moat around the business that has given us competitive advantage, continue to drive performance, particularly around our proprietary solutions, our reputation in quality, reliability and scale on a global basis.
We have an attractive business model that drives long-term construct growth of 7% to 9% organic growth and also margin expansion. Majority of that expansion is driven by mix shift, which I’ll explain shortly. But the underlying drivers of that growth is really evolving around our high-value product components. It’s
Read the full article here
